English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

To investigate the effects of a new non-NMDA antagonist on the trisynaptic pathways in the hippocampus, the author examined the kainate(KA)-induced generalized seizures in rats. A novel non-NMDA antagonist, YM90K, showed the blockade of the Schaffer collaterals in a 2-deoxyglucose study (2-DG) and that the CA1-2 pyramidal cells of the hippocampus were preserved seven days after the KA injections. On the other hand, the control and MK-801 (NMDA-antagonist) treated rats did not depress the Schaffer collaterals and showed persistent hypermetabolism of glucose in the CA1 pyramidal cell layer, where neurons were not preserved seven days later. 2-DG was useful to reveal the effects of a non-NMDA antagonist on the KA-induced generalized seizures. This suggests that YM90K is a potent non-NMDA antagonist and that it has a neuroprotective effect in rats.

A New Non-NMDA Antagonist Modifies the Local Cerebral Glucose Utilization in Kainate-induced Generalized Seizure